RE:RE:RE:RE:RE:RE:RE:G12D/G12V KRAS mutation in PC & CRC patients respond to PelaJuly 30, 2024 - Incyte's latest list of discontinued assets includes both of Incyte’s oral, small-molecule PD-L1 inhibitors that were being assessed in phase 1 trials. One of these, INCB99280, was being evaluated in an early-stage solid tumor trial, and the biotech had already set out plans for a phase 1/1b trial in KRASG12C-mutated solid tumors in combination with Bristol Myers Squibb’s Krazati.
The other scrapped PD-L1 inhibitor, dubbed INCB99318, was also in a phase 1 solid tumor trial. Also on the chopping block are a couple of LAG3 drug candidates. One of these is a LAG-3 monoclonal antibody dubbed INCAGN2385 that was being developed with Agenus. The other was a bispecific anti–PD1 and anti–LAG-3 antibody dubbed INCA32459 that was being developed with Merus and had undergone a phase 1 study in select advanced malignancies.
Finally, Incyte has removed a TIM-3 monoclonal antibody dubbed INCAGN2390, which was another product of the Merus collaboration. INCAGN2390 was designed to “potently block TIM-3 to reinvigorate T and NK cells and reduce immunosuppression by regulatory T cells (Tregs),” according to Agenus’ website.
Despite today’s pipeline changes, oncology remains another key area of focus for Incyte, which will continue to channel resources into NCB123667—a CDK2-selective small molecule inhibitor in a phase 1 solid tumor trial—among others.
https://www.fiercebiotech.com/biotech/incyte-drops-pair-pd-l1-drugs-part-second-pipeline-clear-out-year